IP Library Granted Patent US 12,036,240
Granted Patent B2
US 12,036,240 · App. 16/442,348 · Granted Jul 16, 2024

Compositions and methods targeting complement component 3 for inhibiting tumor growth

Inventors: Aviv Regev (Cambridge, MA); Ana Carrizosa Anderson (Boston, MA); Ayshwarya Subramanian (Cambridge, MA); Orit Rozenblatt-Rosen (Cambridge, MA)
Assignees: The Broad Institute, Inc.; Massachusetts Institute of Technology; The Brigham and Women's Hospital, Inc.
A61K35/17C07K14/7051C07K14/70596C07K16/2818C07K16/2827
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,036,240
App. No.
16/442,348
Granted
Jul 16, 2024
Kind
B2
Abstract

This invention relates generally to compositions and methods for modulating complement component 3 (C3) activity or expression to treat, control or otherwise influence tumors and tissues, including cells and cell types of the tumors and tissues, and malignant, microenvironmental, or immunologic states of the tumor cells and tissues. The invention also relates to methods of diagnosing, prognosing and/or staging of tumors, tissues and cells.

Claims (32)

1. A method of activating cancer associated fibroblasts (CAFs) ex vivo comprising eliminating expression of complement component 3 (C3) in CAFs obtained from a subject having cancer,

wherein the expression of C3 is eliminated by expression of a CRISPR system directed to a C3 gene in the CAFs,

wherein the activated CAFs comprise increased expression of Ccl5 as compared to CAFs where C3 is not eliminated, and

wherein the activated CAFs increase tumor-infiltrating lymphocytes (TILS) in a tumor of the subject.

2. The method of claim 1 , wherein the activated CAFs further comprise expression of:

Car4, Mtrr, Fosl1, Cdca2, Mex3d, Gjb5, Tcfl5 and Rbml2; or

Gli1, Gli2, Ccl19, Cd52, Wnt4, Wntl1, Ctu1, Ccr5, Cd68, Wnk4, H2-Q1, H2-Q2, H2-Ob, Slfn1, Slfn4, Slfn9, Slfn8, Fgfl2, Kcnkl2, Fcgr4, Clcn1, Clcn2, Kcnkl2 and 117; or

Cfp, C1qa, C1rl and C5ar1.

3. The method of claim 1 , further comprising adoptively transferring the activated CAFs to the subject.

4. The method of claim 3 , wherein adoptively transferring the activated CAFs decreases lymphangiogenesis in a tumor of the subject.

5. The method of claim 3 , wherein adoptively transferring the activated CAFs is administered in combination with an immunotherapy.

6. The method of claim 5 , wherein the immunotherapy is an immune checkpoint blockade therapy or an adoptive T cell therapy.

7. The method of claim 6 , wherein the immune checkpoint blockade therapy comprises anti-TIM3, anti-CTLA4, anti-PD-L1, anti-PD1, anti-TIGIT, anti-LAG3, or combinations thereof.

8. The method of claim 6 , wherein the adoptive T cell therapy comprises CAR T cell therapy.

9. The method of claim 1 , wherein the cancer comprises a cancer of blood, kidney, skin, bone, bladder, colon, brain, breast, head, neck, endometrium, lung, testes, ovary, pancreas, or prostate.

10. The method of claim 1 , further comprising detecting podoplanin (PDPN) expression in CAFs.

11. The method of claim 1 , wherein the activated CAFs further comprise expression of one or more genes selected from the group consisting of Tcf24, Slco5a1, 6720483E21Rik, Gm29107, Npas2, 4930558J18Rik, Ino80dos, Tmem169, Catip, Plcd4, Sphkap, Fbxo36, Glrp1, Gm19589, Agxt, Rnfl52, Serpinb5, Gli2, 2900009J06Rik, Mfsd4, Klhdc8a, Lgr6, Kcnt2, Pdc, Serpinc1, Dars2, XcII, Cd247, Gm16701, Lmx1a, Fcgr4, Gm20045, B930036N10Rik, Igsf9, 01fr433, Opn3, Chm1, Kif26b, 1700056E22Rik, Gm34342, 4930532G15Rik, Kcnk2, Proser2, Gata3, 4930426L09Rik, Thnsl1, 1700084E18Rik, 1700001022Rik, Cfap157, Zbtb43, Lmxlb, Phfl9, Crb2, Wdr38, Lypd6, Scn2a1, Mettl5os, 2600014E21Rik, Rbm45, Zfp385b, Gm13715, Clgtnf4, Spi1, Ambra1, Abtb2, Tcpl111, Mettl15, Gm26899, Catsper2, Blocls6os, 1810024B03Rik, Gm14029, AV099323, Mcm8, Ism1, Slc52a3, Defb25, Mylk2, Rbml2, Gm14286, Fam209, Gm20721, Gm14325, Gm14327, Phactr3, Tcfl5, Nkain4, Col20a1, Nudt10, Rpgr, Gm26652, Jade3, Uspl1, Cfp, 2310010G23Rik, Smim1012a, Xlr3a, Xlr3c, Pdzd4, Tab3, Gm14798, Spin4, Eda2r, Dlg3, Ercc61, C77370, Uprt, MumlI1, Pfkfb1, Nhs, Ofd1, Prps2, 117, Zbtb10, C030034L19Rik, Naaladl2, Lrrc34, Usp13, Gm15952, D3Ertd254e, 1810062G17Rik, Fgf2os, D3Ertd751e, Gm30074, Ccdc169, P2ry1, Gm6634, Map9, Rbm46, Crabp2, Gm3764, Gm16069, Muc1, S100a14, S100a3, S100a7a, Tchh, Ctss, Ciart, Hist2h3c2, Hist2h2aa1, Zfp697, Dennd2c, Ptpn22, Atxn712, Dpyd, A530020G20Rik, Prss12, Gm43254, Lpar3, Spata1, Gdf6, Rad54b, Rragd, Tmem215, Kif24, AI464131, Ccl19, Gm26881, Zbtb5, Palm2, Akap2, Tnfsfl5, Ptprd, Cdkn2a, E130102H24Rik, Pars2, Echdc2, Dmrta2, Bend5, Sti1, Faah, Tmem69, Hpd1, Col8a2, Gm12942, Gjb5, Tmem54, Gm12976, Serinc2, Cd52, Ubxnl1, Runx3, 6030445D17Rik, C1qa, Wnt4, Tmco4, 4921514A10Rik, Gm29367, Gm20707, Casz1, Gpr157, Nol9, Kcnab2, Megf6, B930041F14Rik, Tmem240, Gm16008, Tnfrsfl8, 9430015G10Rik, Sema3a, Fbx113, Napepld, Crygn, Gm7361, Drc1, Fam184b, Selll3, Wdr19, Limch1, Ras1l1b, C530008M17Rik, Spink2, Gm9958, Cdkl2, Nup54, 2010109A12Rik, Fgf5, 1700010H22Rik, Agpat9, Gm29707, Klhl8, Gm42749, Gm28050, A830010M20Rik, Ccdc18, E130006D01Rik, Myolh, Trpv4, Gm10399, Rnft2, Tbx3, Iqcd, Gm42918, 4932422M17Rik, Kntc1, Gm10369, Pilrb1, 6330418K02Rik, Rbak, Zfp316, Gm20635, Alox5ap, Gm19719, D730045B01Rik, D830026I12Rik, Kcp, Tspan33, Klfl4, D630045J12Rik, 4930599N23Rik, Clen1, 1600015I10Rik, Gm16499, Ndnf, Reep1, Atoh8, Mlap, Wdr54, Cm13, Add2, Gm44089, Rab43, Hdacl1, Srgap3, Fancd2, Fxyd4, 4930540M05Rik, Gm26826, C1r1, Ptpn6, Kcna1, Gm10010, Klrbla, Klrk1, Pbp2, Rerg, Gm15704, Pthlh, Far2os1, Mettl20, Tarm1, Gm15510, Zfp583, Zim1, Zfp772, Dhx34, C5ar1, Pnmal2, Zfp94, Tmem91, Rab4b, Itpkc, Zfp607, Zfp568, Zfp382, Gm26810, Krtdap, Lsr, Zfp536, Vsig101, Ctu1, Lrrc4b, Napsa, Lmtk3, Uevld, Fancf, Nipa1, Mkrn3, Lysmd4, Ticrr, Homer2, Sh3gl3, Arnt2, RP24-118K20.1, Rab30, Tenm4, Kctd21, Wnt11, Dgat2, C2cd3, RP23-299D2.2, Folr2, Hbb-bt, Gm15133, Ppfibp2, Pdzd9, 4933440M02Rik, Corola, Gdpd3, Pagrla, Mylpf, Zfp668, 9130023H24Rik, Ifitm5, Sct, Eps812, Syt8, Tnni2, Gm21781, Rgs17, Adat2, Heca, Map7, Eya4, Slcl8b1, Fam26f, Tube1, Slcl6a10, 9030612E09Rik, Bend3, Fam184a, Sh3rf3, Gm5424, 1700120B22Rik, Dnajcl2, Lrrc3, Gm10146, Slcla6, Hcn2, Plppr3, Hmha1, Mex3d, Celf5, Tle6, Zfp873, Gm4924, Glt8d2, Gm15990, Ankslb, Nts, BbsO, Glipr1, Lgr5, Faml9a2, Lrig3, F420014N23Rik, Gi1, Stac3, Gls2, A430046D13Rik, Camsap3, Lrrc8e, RP23-216D14.4, RP23-156J8.1, RP23-366014.5, 3930402G23Rik, Myom2, Xkr5, Nek3, Gm26909, Thap1, Tex15, 6430573F11Rik, AI429214, Msr1, 1700029J07Rik, AcslI, Asb5, Sh2d4a, Zfp963, 1700030K09Rik, Tmem38a, Cedc130, Ckslbrt, Neto2, 9330175E14Rik, Gm3830, Nol3, Rltpr, Ddx28, Pdpr, Spata21, 2810455005Rik, Kcnk1, 6230400D17Rik, Plau, Dnah12, Tnne1, Ncoa4, Lrrcl8, Gdfl0, A630023A22Rik, 2610528A11Rik, Pnp2, S1c39a2, Tgm1, Phflla, Phfl1c, Setdb2, Gm27010, Wdfy2, Neil2, Blk, Fam167a, Ptk2b, Cdca2, Nefm, Nef1, Gm27222, Gm16867, Hr, Dmtn, Cysltr2, Tnfsfl1, Pcdh9, Tpm3-rs7, Ggact, Trpc6, Vstm5, Gm7808, Swsap1, Rgl3, Zfp653, Gm16845, Cnn1, Tbx20, Tmem136, Nlrx1, Hinfp, Ube4a, Plet1, 2310030G06Rik, Gm7293, Elmod1, Lingo1, Rec114, Zwilch, Snx22, Car12, Fam8la, 4933433G15Rik, A130057D12Rik, Lea5, Elovl4, 9430037G07Rik, Adamts7, 4933400C23Rik, Slc9a9, Nphp3, Col6a5, Glyctk, Mstlr, Traip, Col7a1, Als2c1, Gm2415, Acaalb, Acvr2b, Ulk4, Cck, Lyzl4, Cer5, Lif, RasI10a, Nacad, Gm12056, Zrsr1, Papolg, Adralb, Trim7, Col23a1, Jade2, Cdkl3, Fam183b, 2810021J22Rik, Gjc2, Jmjd4, Zkscan6, Usp43, 9130213A22Rik, Kcnab3, Efnb3, Cd68, Zmynd15, 4933427D14Rik, Raplgap2, Rph3a1, Gemin4, Dbil5, Atad5, Adap2, Rhbdl3, Tmem132e, Gm11423, Slfn9, Slfn8, Slfn1, Slfn4, RasI10b, Dusp14, Myol9, Car4, Rad51c, Pctp, Cdc34b, Dlx3, Dlx4, Gm11520, Famll7a, Skap1, Cacnb1, Rapgefl1, Gm11940, Krt36, Hap1, Wnk4, Aarsd1, Gm11551, Nags, Gm11627, 2810433D01Rik, 2410004I01Rik, Arhgap27os2, Milr1, Polg2, Rgs9, D11Wsu47e, Galr2, Mgat5b, Tbcldl6, Aatk, Sectmla, B3gntl1, Heatr1, Ero1lb, Vdac3-ps1, Gpr141, Hist1h2 bp, Hist1h2bk, Hist1h4h, Hist1h3d, Hist1h4c, Hist1h2ab, Hist1h3a, Lrrcl6a, Gm26735, Serpinb1b, Bmp6, Sirt5, Nhlrc1, A830005F24Rik, Ptpde1, Ippk, Omd, Diras2, Syk, Gm5449, Unc5a, Fancc, Cdcl4b, 1810034E14Rik, Gm37276, Mtrr, Adamtsl6, Cep72, Gm17259, Rasgrf2, Msh3, Mtx3, Cmya5, S100z, Gm6169, Gm26619, Gm9828, Naip2, Naip6, Ppwd1, Gm10735, Hen1, Gm7120, Gm26520, Fam228b, Kcns3, Greb1, 5730507CO1Rik, Gm3944, Gm10479, 2410018L13Rik, 9030624G23Rik, Taf1b, Dus41, Ispd, Prpsll3, Gpr135, 4930447C04Rik, Tmem30b, Hspa2, Exd2, Zfyve1, 2410016006Rik, Acot4, Dnal1, Pnma1, Lin52, Gm16381, Eml5, Serpina3f, Wdr25, Tecpr2, Amn, Gm266, 2810029C07Rik, Ptger4, Fyb, Slc1a3, 4930556M19Rik, Fbxl7, Nipal2, Spag1, Baalc, Lrpl2, Zfpm2, Angpt1, Has2, Gm16006, Gsdmc, Zfat, Ly6k, Gm1, Mapkl5, Nrbp2, Smpd5, Kifc2, Gpt, Zfp251, Apol7a, Phf21b, Ppp6r2, Alg10b, Prickle1, A130051J06Rik, Slc4a8, Krt7, Soat2, Gm26518, Hoxc5, D930007P13Rik, Slx4, Sr1, 2610020C07Rik, Snx29, 3110001I22Rik, Pkp2, Gm15648, Rtn4r, Tbx1, Clcn2, Chrd, BC106179, Cldn1, Fgfl2, Bdh1, Ccdcl4, Zbtbllos1, Evalc, Dopey2, Zfp97, Gm7535, Zfp944, Kifc5b, Syngap1, Ip6k3, Gm26549, Zfp811, Zfp799, Zfp870, Zfp563, Myolf, H2-Ob, Aif1, H2-Q1, H2-Q2, Pou5f1, Gm20442, Ppplrl8os, BC023719, Gm8909, Ankrd66, Enpp5, 1600014C23Rik, Rsph9, Cul9, Plcl2, Prr22, Vav1, Cdkl4, Thumpd2, Kcnkl2, Gm6225, Gm17430, Dsc2, Rprdla, Gm3550, Prob1, Pcdhbl7, Gprl51, Eif3j2, Cdo1, Enolb, Dtwd2, Gm4841, Spink10, Pmaip1, Lipg, Katnal2, 8030462N17Rik, Epg5, Hsbpll1, Sytl2, Fosl1, Ctsw, Ccdc88b, Macrod1, Pcna-ps2, Best1, Ms4a6b, Mpeg1, Vps13a, 2410080I02Rik, 4430402I18Rik, Cd274, Ranbp6, Rnls, Exoc6, Sorbs1, Tctn3, Slit1, Lox14, Neurlla, Gpam, B230217012Rik, and Sfxn4.

12. A method of increasing tumor-infiltrating lymphocytes (TILS) in a tumor of a subject having cancer comprising:

obtaining cancer associated fibroblasts (CAFs) from a tumor of the subject; activating the CAFs by ex vivo eliminating expression of complement component 3 (C3) in the CAFs by expressing a CRISPR system directed to a C3 gene in the CAFs,

wherein the activated CAFs comprise increased expression of Ccl5 as compared to CAFs where C3 is not eliminated; and

adoptively transferring the activated CAFs to the subject.

13. The method of claim 12 , further comprising isolating CAFs that do not express PDPN from the activated CAFs before adoptively transferring the activated CAFs to the subject.

14. The method of claim 12 , wherein the activated CAFs further comprise expression of:

Car4, Mtrr, Fosl1, Cdca2, Mex3d, Gjb5, Tcfl5 and Rbm12; or

Gli1, Gli2, Ccl19, Cd52, Wnt4, Wntl1, Ctu1, Ccr5, Cd68, Wnk4, H2-Q1, H2-Q2, H2-Ob, Slfn1, Slfn4, Slfn9, Slfn8, Fgfl2, Kcnkl2, Fcgr4, Clcn1, Clcn2, Kcnkl2 and 117; or

Cfp, C1qa, C1rl and C5ar1.

15. The method of claim 12 , wherein adoptively transferring the activated CAFs decreases lymphangiogenesis in a tumor of the subject.

16. The method of claim 12 , wherein adoptively transferring the activated CAFs is administered in combination with an immunotherapy.

17. The method of claim 16 , wherein the immunotherapy is an immune checkpoint blockade therapy or an adoptive T cell therapy.

18. The method of claim 17 , wherein the immune checkpoint blockade therapy comprises anti-TIM3, anti-CTLA4, anti-PD-L1, anti-PD1, anti-TIGIT, anti-LAG3, or combinations thereof.

19. The method of claim 17 , wherein the adoptive T cell therapy comprises CAR T cell therapy.

20. The method of claim 12 , wherein the cancer comprises a cancer of blood, kidney, skin, bone, bladder, colon, brain, breast, head, neck, endometrium, lung, testes, ovary, pancreas, or prostate.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2020
From: SUBRAMANIAN, AYSHWARYA
To: THE BROAD INSTITUTE, INC.
Reel/Frame 053856/0986 →
CONFIRMATORY LICENSE Recorded Feb 18, 2020
From: BROAD INSTITUTE INC
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 051961/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2020
From: ANDERSON, ANA CARRIZOSA
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 051814/0102 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2019
From: REGEV, AVIV
To: THE BROAD INSTITUTE, INC.; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 050956/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2019
From: ROZENBLATT-ROSEN, ORIT
To: THE BROAD INSTITUTE, INC.
Reel/Frame 050748/0861 →
Continuity (2)
Provisional Application 62685268 · Jun 14, 2018
Related Publication 20200023007A1 · Jan 23, 2020